Transgene S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alessandro Riva
- Full Time Employees
- 144
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400, Boulevard Gonthier d’Andernach Illkirch-Graffenstaden France 67405
- IPO Date
- Jan 8, 2021
- Website
- transgene.fr
- Similar Companies
- Business
- Transgene S.A. (Ticker: TRGNF) is a clinical-stage biotechnology company that develops targeted immunotherapies for the treatment of solid tumors and infectious diseases. The company offers a portfolio of product candidates including oncolytic viruses such as TG6002, a vaccinia virus engineered to express FCU1 gene for systemic administration in liver cancers; TG4010, a viral vector vaccine based on modified vaccinia virus Ankara encoding MUC1 antigen and IL-2 for non-small cell lung cancer; and TG4001, a therapeutic vaccine targeting HPV16 for virus-associated cancers; as well as antibody therapeutics like BT-001, an oncolytic virus expressing anti-CTLA4 antibody, and precision immunotherapies such as TG4050, an individualized cancer vaccine using AI-driven neoantigen selection. These therapies leverage viral vectors, oncolytic viruses, and next-generation antibodies to activate the immune system against cancer cells. Transgene operates primarily in the oncology and infectious disease segments, targeting pharmaceutical companies, biotechs, and academic institutions as partners, with geographic focus on Europe, North America, and Asia. Founded in 1979 and headquartered in Strasbourg, France, the company maintains subsidiaries including Transgene Biotek in India for manufacturing support. In the last 1-2 years, Transgene has advanced several clinical programs, including positive Phase I data for TG4001 in HPV-negative head and neck cancers announced in 2024; expanded collaborations with AstraZeneca for next-generation oncolytic viruses under a multi-year research pact renewed in 2023; and initiated dosing in the Phase I trial of BT-001 in combination with pembrolizumab for solid tumors in partnership with BioNTech, with updates reported in early 2025. Additionally, the company secured non-dilutive funding through French government grants for infectious disease programs and launched pre-clinical work on new candidates targeting solid tumors. These developments underscore Transgene's strategic shift toward combination immunotherapies and AI-integrated platforms to accelerate pipeline progression.
Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
BioInvent and Transgene's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments
Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript